Neurofibromatosis 1 is one of the more common in heritable disorders that surgeons may encounter. A plethora of systemic associations, both benign and malignant, can affect these patients, and an acute awareness of these associations is essential for proper surgical care. A complete review of this disorder from the surgical perspective follows, highlighting the importance of this awareness. A brief review on the management and follow-up of surgical malignancies associated with this disorder is included.
Get full access to this article
View all access options for this article.
References
1.
National Institutes of Health Consensus Development Conference Statement: Neurofibromatosis.Bethesda, MD, USA July 13–15, 1987.Neurofibromatosis1988; 1: 172–8.
2.
LegiusE., MarchukD.A., CollinsF.S., GloverT.W.Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumor suppressor gene hypothesis.Nat Genet1993; 3: 122–6.
3.
McCorkmickF.ras GTPase activating protein: Signal transmitter and signal terminator.Cell1989; 13: 5–8.
4.
XuG., O'ConnellP.O., ViskochilD.The neurofibromatosis 1 gene encodes a protein related to GAP.Cell1990; 62: 599–608.
5.
BallesterR., MarchukD., BoguskiM.The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins.Cell1990; 63: 851–9.
6.
BosJ.L.Ras oncogenes in human cancer: A review.Cancer Res1989; 49: 4682–9.
7.
RiccardiV.M., LewisR.A.Penetrance of von Recklinghausen Neurofibromatosis: A distinction between predecessors and descendants.Am J Hum Genet1988; 42: 284–9.
8.
MulvihillJ.J., ParryD.M., ShermanJ.L.Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis): An update.Ann Intern Med1990; 113: 39–52.
9.
JadayelD., FainP., UpadhyayaM.Paternal origin of new mutations in von Recklinghausen neurofibromatosis.Nature1990; 343: 558–9.
10.
WoodruffJ.M.Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis.Sem Med Genet1999; 89: 23–30.
11.
OzonoffS.Cognitive impairment in neurofibromatosis type 1.Semin Med Genet1999; 89: 45–52.
12.
NorthK.N., RiccardiV., Samango-SprouseC.Cognitive function and academic performance in neurofibromatosis 1: Consensus statement from the NF 1 cognitive disorders task force.Neurol (Tokyo)1997; 48: 1121–7.
13.
RuggieriM.The different forms of neurofibromatosis.Childs Nerv Syst1999; 15: 295–308.
14.
PollackI.F., ShultzB., MulvihillJ.J.The management of brainstem gliomas in patients with neurofibromatosis 1.Neurol (Tokyo)1996; 46: 1652–60.
15.
MolloyP.T., BilaniukL.T., VaughanS.N.Brainstem tumors in patients with neurofibromatosis type 1.Neurol (Tokyo)1995; 45: 1897–902.
LinD., BarkerP.Neuroimaging of phakomatoses.Semin Pediatr Neurol2006; 13: 48–62.
18.
Brunetti-PierriN., DotyS., HicksJ.Generalized metabolic bone disease in Neurofibromatosis type 1.Mol Genet Metab2008; 94: 105–11.
19.
StevensonD.A., BirchP.H., FriedmanJ.M.Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1.Am J Med Genet1999; 84: 413–9.
20.
VitaleM.G., GuhaA., SkaggsD.L.Orthopaedic manifestations of neurofibromatosis in children: An update.Clin Orthop Relat Res2002; 107–18.
21.
CrozierW.C.Upper airway obstruction in neurofibromatosis.Anaesthesia1987; 42: 1209–11.
22.
RyuJ.H., ParambilJ.G., McGrannP.S., AughenbaughG.L.Lack of evidence for an association between neurofibromatosis and pulmonary fibrosis.Chest2005; 128: 2381–6.
23.
ZamoraA.C., CollardH.R., WolterP.J.Neurofibromatosis-associated lung disease: A case series and literature review.Eur Respir J2007; 29: 210–4.
24.
YokoyamaA., KohnoN., SakaiK.Distal acinar emphysema and interstitial pneumonia in a patient with von Recklinghausen's disease: Five year observation following quitting smoking.Intern Med1997; 36: 413–6.
25.
HuppmanJ.L., GathonV., BowersV.D.Neurofibromatosis and arterial aneurysm.Am Surg1996; 62: 311–31.
26.
SalyerW.R.The vascular lesions of neurofibromatosis.Angiol1974; 8: 510–9.
27.
StewartD.R., CoganJ.D., KramerM.R.Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy?Chest2007; 132: 798–808.
28.
EngelP.J., BaughmanR.P., MenonS.G.Pulmonary hypertension in neurofibromatosis.Am J Cardiol2007; 99: 1177–8.
29.
Hassen-KhodjaR., DeclemyS., BattM.Visceral artery aneurysms in von Recklinghausen's neurofibromatosis.J Vasc Surg1997; 25: 572–5.
30.
FossaliE., SignoriniE., IntermiteR.C.Renovascular disease and hypertension in children with neurofibromatosis.Pediatr Nephrol2000; 14: 806–10.
31.
TedescoM.A., DiSalvoG., RattiG.Arterial distensibility and ambulatory blood pressure monitoring in young patients with neurofibromatosis type 1.Am J Hypertens2001; 14: 559–66.
FullerC.E., WilliamsG.T.Gastrointestinal manifestations of type 1 neurofibromatosis (von Recklinghausen's disease).Histopath1991; 19: 1–11.
34.
SicaG.S., SujendranV., WarrenB., MaynardN.D.Neurofibromatosis of the esophagus.Ann Thorac Surg2006; 81: 1138–40.
35.
KimH.R., KimY.J.Neurofibromatosis of the colon and rectum combined with other manifestations of von Recklinghausen's disease.Dis Colon Rectum1998; 41: 1187–92.
36.
FeinstatT., TeslukH., SchufflerM.D.Megacolon and neurofibromatosis: A neuronal intestinal dysplasia.Gastroenterology1984; 86: 1573–9.
37.
BuckL., PerryB., RichardsM.Periampullary carcinoid tumor in a woman with neurofibromatosis.Curr Surg2006; 63: 252–4.
38.
GriffithsD.F.R., WilliamsG.T., WilliamsE.D.Duodenal carcinoid tumours, phaeochromocytoma and neurofibromatosis: Islet cell tumour, phaeochromocytoma and the von hippel-lindau complex: Two distinctive neuroendocrine syndromes.Q J Med1987; 64: 769–82.
39.
BauschB., BorozdinW., NeumannH.P.H.Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma.N Engl J Med2006; 25: 2729–31.
40.
LewJ.I., JacomeF.J., SolorzanoC.C.Neurofibromatosis-associated pheochromocytoma.J Am Coll Surg2005; 202: 550–1.
41.
PerezE.A., LivingstoneA.S., FranceschiD.Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors.J Am Coll Surg2006; 202: 623–9.
42.
MiettienenM., FetschJ.F., SobinL.H., LasotaJ.Gastrointestinal stromal tumors in patients with neurofibromatosis 1: A clinicopathologic and molecular study of 45 cases.Am J Surg Pathol2006; 30: 90–6.
CacevT., RadosevicS., SpaventiR.NF 1 gene loss of heterozygosity and expression analysis in sporadic colon cancer.Gut2005; 54: 1129–35.
45.
EckertL.B., RepaskyG.A., UlkuA.S.Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis.Cancer Res2004; 64: 4585–92.
46.
SharifS., MoranA., HusonS.M.Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening.J Med Genet2007; 44: 481–4.
47.
DeSchepperS., BoucneauJ., LambertJ.Pigment cell-related manifestation in neurofibromatosis type 1: An overview.Pigment Cell Res2005; 18: 13–24.
48.
SchafferJ.V., ChangM.W., KovichO.I.Pigmented plexiform neurofibroma: Distinction from a large congenital melanocytic nevus.J Am Acad Dermatol2007; 56: 862–8.
49.
RiccardiV.M.Pathophysiology of neurofibromatosis. Dermatologic insights into heterogeneity and pathogenesis.J Am Acad Dermatol1980; 3: 157–66.
50.
RubbenA., BauschB., NikkelsA.Somatic deletion of the NF 1 gene in a neurofibromatosis type 1 associated malignant melanoma demonstrated by digital PCR.Mol Cancer2006; 5: 36.
51.
AndersonL.B., FountainJ.W., GutmannD.H.Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines.Nature1993; 3: 118–21.
52.
GuillotB., DalacS., DelaunayM.Cutaneous malignant melanoma and neurofibromatosis type 1.Melanoma Res2004; 14: 159–63.
53.
KarM., DeoS.V.S., ShuklaN.K.Malignant peripheral nerve sheath tumors (MPNST) Clinicopathological study and treatment outcome of twenty four cases.W J Curg Onc2006; 4: 55.
54.
FernerR.E., GutmanD.H.International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis 1.Can Resear2002; 62: 1573–5.
55.
DucatmanS.B., ScheithauerB.W., PiepgrasD.G.Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases.Cancer1986; 57: 2006–21.
CichowskiK., ShihT.S., SchmittE.Mouse models of tumor development of neurofibromatosis type 1.Science1999; 286: 2172–8.
58.
ZhuY., ParadaL.F.Neurofibromin, a tumor supressor in the nervous system.Exp Cell Res2001; 264: 19–28.
59.
NielsenG.P., Stemmer-RachamimovA.O., InoY.Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation.Am J Pathol1999; 155: 1879–84.
60.
KoureaH.P., Cordon-CardoC., DudasM.Expression of p27kip and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas.Am J Pathol1999; 155: 1885–91.
61.
KoureaH.P., OrlowI., ScheithauerB.W.Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas.Am J Pathol1999; 155: 1855–9.
62.
HoltkampN., OkuducuA.F., MuchaJ.Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.Carcinogenesis2006; 27: 664–71.
63.
KingA., DeBaunM.R., RiccardiV.M., GutmannD.H.Malignant peripheral nerve sheath tumors in eurofibromatosis.Am J Med Genet2002; 39: 311–4.
MautnerV.F., FriedrichR.E., von DeimlingA.Malignant peripheral nerve sheath tumours in neurofibromatosis type 1: MRI supports the diagnosis of malignant plexiform neurofibroma.Neuroradiology2003; 45: 618–25.
67.
FernerR.E., LucasL.D., O'DohertyM.J.Evaluation of 18 fluorodeoxyglucose positron emission tomography (18FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.J Neurol Neurosurg Psychiatry2000; 68: 353–7.
68.
CardonaS., SchwarzbachM., HinzU.Evaluation of F 18 deoxyglucose positron emission tomography (FDG PET) to assess the nature of neurogenic tumors.Eur J Surg Oncol2003; 29: 536–41.
69.
WolkensteinP., ZaleskiI.D., MorenoJ.C.Cost evaluation of the medical management of neurofibromatosis 1: A prospective study on 201 patients.Br J Derm2000; 142: 1166–70.
70.
GutmannD.H., AylsworthA., CareyJ.C.The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.JAMA1997; 278: 51–7.
71.
WolkensteinP., FrecheB., ZellerJ., RevuzJ.Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients.Arch Dermatol1996; 132: 1333–6.
72.
DrappierJ.C., KhosrotehraniK., ZellerJ.Medical management of neurofibromatosis 1: A cross-sectional study of 383 patients.J Am Acad Dermatol2003; 49: 440–4.
73.
WalkerL., ThompsonD., EastonD.A prospective study of neurofibromatosis type 1 cancer incidence in the UK.Br J Cancer2006; 95: 233–8.
74.
ZollerM.E.T., RembeckB., OdenA.Malignant and benign tumours in patients with neurofibromatosis type 1 in a defined Swedish population.Cancer1997; 79: 2125–31.
75.
RasmussenS.A., YangA., FriedmanJ.M.Mortality in neurofibromatosis 1: An analysis using US death certificates.Am J Hum Genet2001; 68: 1110–8.
